Outlook Therapeutics Joins Piper Sandler Annual Conference
ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a dynamic biopharmaceutical company, is taking significant steps in the treatment of retinal diseases. The company has announced that its Chief Executive Officer, Bob Jahr, will engage in a fireside chat at the prestigious Piper Sandler 37th Annual Healthcare Conference.
Event Schedule and Engagement
This important discussion is set to take place on an upcoming Tuesday at 10:00 AM ET. The fireside chat is a fantastic opportunity for Bob Jahr to share the innovative approaches that Outlook Therapeutics is implementing to enhance patient care in retinal wellness.
Beyond the fireside chat, there will be opportunities for one-on-one in-person discussions with members of the investor community registered for the event. This personal interaction allows investors to delve deeper into the company’s vision and strategic initiatives.
Live Webcast Access
For those unable to attend the conference in person, a live webcast of the fireside chat will be accessible through the company’s official website. The webcast will be available for viewing following the event, ensuring that all interested parties can engage with the insights shared.
Understanding Outlook Therapeutics’ Mission
Outlook Therapeutics is dedicated to developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma), striving to set a new standard in care for retinal diseases. Notably, LYTENAVA™ became the first ophthalmic formulation of bevacizumab to receive the necessary marketing authorization from the European Commission and the MHRA for the treatment of wet age-related macular degeneration (AMD).
Currently, Outlook Therapeutics has launched LYTENAVA™ in Germany and the UK, marking a significant milestone in providing new treatment options for patients battling wet AMD.
Innovative Approaches
As the company navigates through investigational phases in the United States, ONS-5010/LYTENAVA™ aims to be the pioneering ophthalmic formulation of bevacizumab approved for retinal applications when it reaches the market. This potential breakthrough could transform how conditions like wet AMD are treated, giving hope to many individuals affected by vision loss.
Investor Relations Contact
For additional inquiries, Jenene Thomas, the Chief Executive Officer of JTC Team, LLC, welcomes communication from investors. She can be reached directly at 908.824.0775. Investors wishing to send emails can do so at OTLK@jtcir.com. It is vital for the investor community to maintain open lines of communication as Outlook Therapeutics progresses along its exciting journey.
Frequently Asked Questions
1. What is the focus of Outlook Therapeutics?
Outlook Therapeutics focuses on enhancing treatments for retinal diseases through innovative biopharmaceutical solutions.
2. When is Outlook Therapeutics' fireside chat scheduled?
The fireside chat is scheduled for Tuesday, at 10:00 AM ET during the Piper Sandler Annual Healthcare Conference.
3. How can investors access the live webcast?
Investors can view the live webcast of the fireside chat on the company’s website.
4. What is LYTENAVA™?
LYTENAVA™ is an ophthalmic formulation of bevacizumab developed by Outlook Therapeutics for treating wet AMD.
5. Who can investors contact for more information?
Investors can contact Jenene Thomas at JTC Team, LLC for inquiries related to Outlook Therapeutics.